title: Plasma levels of tricyclic antidepressants and clinical efficacy: review of the literature -- part II.
abstract: The authors have critically reviewed the literature regarding the relationship between plasma levels of tricyclic antidepressant and their clinical efficacy. When available, drug-drug interactions, pharmacokinetics, and other factors influencing plasma levels of tricyclic antidepressants are discussed. Although many studies are confounded by significant methodological and statistical problems, it appears to these reviews that the available evidence suggests a curvilinear relationship between nortriptyline plasma levels and antidepressant efficacy in tricyclic responsive endogenously depressed inpatients, with maximal therapeutic efficacy achieved with notriptyline plasma levels between 50-175 ng/ml. The evidence for imipramine supports a linear relationship between plasma levels of imipramine plus desmethylimipramine and clinical response in nondelusional endogenously depressed tricyclic responsive inpatients. For amitriptyline, the picture is less clear. However, with the exception of one well-controlled study, the available evidence suppprts some significant relationship between amitriptyline plus nortriptyline plasma levels and antidepressant efficacy in tricyclic respoonsive endogenously depressed patients, but it is not clear as to whether this is a linear relationship or a curvilinear one. For the other antidepressants: protriptyline, desmethylimipramine, doxepin, clomipramine, maprotiline, and butriptyline, a significant relationship (if any) awaits further elucidation. It is important to point out that these plasma level relationships probably do no generalize to other types of depressions (e.g. neurotic, characterological, delusional, acute situationa, etc.) and clearly do not apply to every endogenous tricyclic responsive patient. /owever, it appears that, in general, a clinician will obtain therapeutic efficacy for endogenously depressed patients if these guidelines are followed. The actual therapeutic levels will depend on the assay's sensitivity and specificity and may vary from center to center, illustrates the importance of each center defining its own therapeutic limits, or conversely all centers adoptina a universal reproducible assay methodology for each compound measured. Despite these limitations, these reviewers feel that routine monitoring of plasma levels of the tricyclic antidepressants is a useful method to maximize therapeutic efficacy and prvent undue side effects, as well as to insure good medication compliance.
mesh_terms: D000929:Antidepressive Agents, Tricyclic / Q000097:blood* / Q000627:therapeutic use; D001711:Biotransformation; D002997:Clomipramine / Q000097:blood; D003863:Depression / Q000097:blood / Q000188:drug therapy*; D003891:Desipramine / Q000097:blood / Q000134:cerebrospinal fluid; D003986:Dibenzocycloheptenes / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004316:Doxepin / Q000097:blood; D004347:Drug Interactions; D006801:Humans; D007099:Imipramine / Q000097:blood / Q000134:cerebrospinal fluid; D008376:Maprotiline / Q000097:blood; D011530:Protriptyline / Q000097:blood
chemical_list: D000929:Antidepressive Agents, Tricyclic; D003986:Dibenzocycloheptenes; D004316:Doxepin; D008376:Maprotiline; D011530:Protriptyline; D002997:Clomipramine; D007099:Imipramine; D003891:Desipramine